Hosted on MSN10h
Inhalable gene therapy tested for cystic fibrosis treatment in the UK and Europe
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
Oxford Biomedica to support Boehringer Ingelheim’s LENTICLAIR 1 trial
OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...
Medscape2d
Novel Triple Combination Therapy May Transform Cystic Fibrosis Care in Children
Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
EurekAlert!1d
Novel inhalable gene therapy trialled for people with cystic fibrosis
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.
PharmiWeb16h
Cystic Fibrosis Market: Trends, Insights, and Growth Projections 2025-2035
The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...
Too Old to Operate3d
Evaluation of clinical practice guidelines on treatment of cystic fibrosis: A systematic review.
Despite the existence of numerous clinical practice guidelines (CPGs) for cystic fibrosis (CF), there is limited understanding of their credibility and consistency. This systematic review aims to ...
Rolling Out1d
7 rare diseases parents might pass to their children
From life-altering genetic conditions to promising new treatments, here's what you need to know about 7 inherited diseases ...
Everything to know about cystic fibrosis and what causes it
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
The Lancet8d
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta
The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood.
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
Armed robbery in Revesby14h
Inhalable Gene Therapy Trialled for Cystic Fibrosis
Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...